• Patients Debt Collection Protection Act

    The Life and Health Division of the New Mexico Office of Superintendent of Insurance (OSI) protects New Mexicans by ensuring that all life insurance and health insurance policies sold commercially in the State of New Mexico comply with all federal and state laws and regulations.

Starting July 1, 2021, New Mexico law protects low-income people from medical debt collection. The law is called the Patient’s Debt Collection Protection Act.

Debt collection can be selling the debt to a third party, and it can be filing a lawsuit against the patient. Debt collection also can be placing a lien on the patient’s property or garnishing wages. If you are low-income, medical providers cannot take certain debt collection actions against you. Low-income also is called “indigent.” Under New Mexico law, “indigent” means your household income is at or below 200% of the federal poverty guidelines. You can ask your medical provider or the debt collector to decide if you are indigent. You can also check the federal income guidelines to see if you may qualify.

See the Debt Collection Notice below to learn more about your rights. You can fill out the “OSI Attestation of Indigency Form” to claim indigency.

Recent News

Get the latest information about rule changes, legislation, industry information and consumer news.

Read All OSI News

MEDICAL MALPRACTICE PREMIUM REDUCTION

AMENDED BULLETIN 2026-010: The New Mexico State Legislature appropriated $5 million to the New Mexico Office of Superintendent of Insurance (OSI) to address medical malpractice insurance costs for individual providers. The appropriation was part of a supplemental appropriation package passed in 2025. This one-time appropriation directs OSI to provide a premium subsidy for private medical malpractice insurance policies. […]

Read More

NOTICE OF PRESCRIPTION DRUG PRICE TRANSPARENCY ANNUAL MEETING

The Office of the Superintendent of Insurance will hold its annual public meeting to present and discuss the findings and recommendations contained in the 2025 Prescription Drug Price Transparency legislative report. The purpose of this meeting is to inform the public of the report’s contents and to provide an opportunity for public comments and questions. […]

Read More